Rothschild Banker Sees Platform Deals Reshaping India Pharma and Hospital Ownership

The pharmaceutical and healthcare sectors in India are entering a new wave of consolidation, according to Subhakanta Bal, managing director and head of healthcare and consumer for India at the financial advisory group Rothschild and Co. In comments reported on October 25, 2026, Bal said private equity firms and strategic buyers are increasingly building larger, scaled-up businesses through acquisitions and so-called platform building, a buy and build approach in which an investor acquires a strong initial company and then adds smaller firms or brands to expand scale and capability.

Why Buyers Favor Platforms

Bal said the approach makes sense to larger funds for several reasons. The first is scale. The second is the scope to extract efficiencies in procurement, supply chain and overheads. A third is the ability to invest in capability, including technology. He also pointed to an exit perspective, noting that public markets attach a premium to size and attractiveness. His assessment suggests that consolidation is not only about buying assets but about assembling groups that can be run on shared systems and stronger purchasing power.

The trend is expected to support more dealmaking across domestic branded medicines and healthcare services. Bal said local pharma companies are also likely to be active overseas, pursuing specialty products, new markets and attractively valued acquisition targets.

Deals Already Underway

Several transactions illustrate the pattern. ChrysCapital completed the acquisition of a 70.68% stake in Novartis India in July from the parent company, Novartis AG, gaining access to legacy brands such as Voveran, Calcium Sandoz and Tegrital for the domestic market. Since then it has been expanding its portfolio through tie-ups and brand buyouts from multinational companies, including the acquisition of the Indian trademarks for Pfizer's hypertension brand Minipress.

KKR is building a scaled, multi-speciality hospital platform in India. In August it agreed to acquire the India hospital business of Swedish healthcare provider Medicover AB in a deal valued at roughly $1.4 billion. That adds to existing assets including Kerala-based Baby Memorial Hospital, acquired in 2024, and the oncology chain Healthcare Global Enterprises. KKR has been expanding Baby Memorial Hospital through regional acquisitions, such as the 2025 purchase of Kozhikode-based Meitra Hospital. Bal also noted that more interest from local strategic buyers has emerged over the last five years compared with before the COVID-19 pandemic.

What It Means for Health Careers

For people working in hospital services and pharmaceutical operations, consolidation can reshape career paths. When buyers combine facilities and brands, back-office functions such as procurement, supply chain and finance are often merged to capture the efficiencies Bal described. That can mean fewer duplicate roles in administration even as clinical hiring continues, and it places a premium on staff who can work across several sites and standardized systems. On the pharmaceutical side, brand acquisitions bring legacy products under new ownership, which can change how sales, marketing and regulatory teams are organized.

Management and operations skills are likely to matter more as groups grow. Running a multi-site hospital platform requires coordination of purchasing, staffing and quality across facilities, and buyers have said they want to invest in capability, including technology. Workers with experience in practice management, data systems and cross-site coordination may find demand rising, while those in narrow single-site roles could face pressure as functions are centralized.

What to Watch Next

Attention now turns to whether more platform deals follow in branded medicines and hospital services, and whether domestic drug makers complete overseas acquisitions. Bal said the sector is entering a new phase of consolidation, and the deals completed this year show buyers willing to commit large sums to build scale. For workers, the test will be how quickly integration changes staffing structures, which roles are retained at acquired hospitals and brands, and whether the promised investment in technology and capability translates into new skills demand rather than only cost savings.